Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    VANDETANIB

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 6,087Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ESMO: Lilly's RET drug shrinks half of rare thyroid cancers
    ESMO: Lilly's RET drug shrinks half of rare thyroid cancers

    30 Sep 2019

    // A. Al Idrus FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/esmo-lilly-s-ret-drug-shrinks-more-than-half-rare-thyroid-cancers

    A. Al Idrus FIERCE BIOTECH
    30 Sep 2019
    Share Share
    Lilly's RET drug shrinks more than half of rare thyroid cancers
    Lilly's RET drug shrinks more than half of rare thyroid cancers

    29 Sep 2019

    // Amirah Al Idrus FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/esmo-lilly-s-ret-drug-shrinks-more-than-half-rare-thyroid-cancers

    Amirah Al Idrus FIERCE BIOTECH
    29 Sep 2019
    Share Share
    Shrinking 60% of lung cancers, Blueprint's RET drug poised for 2020 filing
    Shrinking 60% of lung cancers, Blueprint's RET drug poised for 2020 filing

    04 Jun 2019

    // Amirah Al Idrus FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/asco-shrinking-60-lung-cancers-blueprint-s-ret-drug-poised-for-2020-filing

    Amirah Al Idrus FIERCE BIOTECH
    04 Jun 2019
    Share Share
    NICE looks to toss Sanofi, Ipsen thyroid cancer drugs from CDF
    NICE looks to toss Sanofi, Ipsen thyroid cancer drugs from CDF

    24 Aug 2017

    // Eric Palmer FIERCE PHARMA

    http://www.fiercepharma.com/pharma/nice-looks-to-toss-sanofi-and-ipsen-thyroid-cancer-drugs-from-cancer-drug-fund

    Eric Palmer FIERCE PHARMA
    24 Aug 2017
    Share Share
    NICE rejects thyroid cancer drugs
    NICE rejects thyroid cancer drugs

    23 Aug 2017

    // Selina McKee PHARMA TIMES

    http://www.pharmatimes.com/news/nice_rejects_thyroid_cancer_drugs_1203075

    Selina McKee PHARMA TIMES
    23 Aug 2017
    Share Share
    AstraZeneca Completes Divestment Of Caprelsa To Genzyme
    AstraZeneca Completes Divestment Of Caprelsa To Genzyme

    06 Oct 2015

    // NASDAQ

    http://www.nasdaq.com/article/astrazeneca-completes-divestment-of-caprelsa-to-genzyme--quick-facts-20151007-00055?

    NASDAQ
    06 Oct 2015
    Share Share